Tesaro, Inc. Details Niraparib Phase 1 Clinical Data Presented at the 2013 American Society of Clinical Oncology Annual Meeting

Published: Jun 04, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO, June 4, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), were presented this morning at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Help employers find you! Check out all the jobs and post your resume.

Back to news